Human papillomavirus detection and typification in cutaneous and mucosal lesions of HIV-seropositive patients.

High-risk human papillomavirus (HPV) in a lesion is related to an increased chance of neoplasic transformation, especially when with immunosuppression, as in HIV infection. We investigated HPV frequency in cutaneous and mucosal lesions of HIV-seropositive male patients. The frequency of malignancy, its association with the HPV type detected and some clinical variables were also assessed. A total of 38 lesions from 27 patients were studied in a period of 18 months. The biopsied fragment was submitted to HPV detection and typification, through polymerase chain reaction with generic (MY09/11) and specific (types 6, 11, 16 and 18) primers. HPV frequency was 63.2%, with detection of HPV types 6, 11 or 16 in 18 lesions and with multi-infection in three. There was low detection of high-risk HPV (type 16, 18.4%) and no HPV type 18. Of the lesions, 36.8% were already premalignant or malignant, and the frequency of moderate or severe dysplasia was higher in the study patients than that described in the HIV-seronegative population. High-risk HPV (type 16) was detected in four benign lesions and low-risk HPV (type 6) in three premalignant genital lesions. There was no significant association between the clinical variables and an increase in the prevalence of premalignant or malignant lesions.

Bowenoid papulosis in a patient with AIDS treated with imiquimod: case report.

A 53-year-old male patient with acquired immunodeficiency syndrome (AIDS) was treated with topical immunomodulator imiquimod for bowenoid papular. Clinically the lesions presented as condilomatous and papulous changes with color varying from skin color to grayish. The lesions were located in the glans and in the dorsum of the penis. Clinical diagnosis was confirmed by histopathological examination, and the polymerase chain reaction (PCR) demonstrated the presence of human papilloma virus (HPV) 16. It was decided to apply a topical treatment with imiquimod 5% cream three times a week for 16 weeks. Almost complete regression was obtained; the residual lesions were treated with a combined chemical cauterization by using 50% trichloroacetic acid followed by 25% podophylin. Although it is not a definitive treatment, the use of topical immunomodulator is one more therapeutic option in the selected HPV cases.

Linfoma cutâneo de células B: relato de caso / Cutaneous B-cell lymphoma: a case report

Os linfomas cutâneos são classificados em linfomas de células B ou de células T, sendo os primeiros menos freqüentes. O linfoma cutâneo de células B (LCCB) pode ser primário ou secundário, tendo o último história natural mais agressiva, com pior prognóstico. Os autores apresentam um caso de LCCB secundário com três anos de evolução, curso indolente, sem envolvimento de outros órgãos além da pele, com ótima resposta ao tratamento quimioterápico. A distinção entre LCCB primário e secundário é muito difícil de ser realizada, uma vez que eles são clínica e histopatologicamente indistinguíveis. Deve-se sempre pesquisar o acometimento de órgãos internos para então definir o prognóstico.